{"id":4054,"date":"2025-05-19T10:27:17","date_gmt":"2025-05-19T10:27:17","guid":{"rendered":"https:\/\/scientificworld.org\/?p=4054"},"modified":"2025-05-19T10:27:20","modified_gmt":"2025-05-19T10:27:20","slug":"new-drug-combination-shows-promise-for-treatment-resistant-colon-cancer","status":"publish","type":"post","link":"https:\/\/scientificworld.org\/?p=4054","title":{"rendered":"New Drug Combination Shows Promise for Treatment-Resistant Colon Cancer"},"content":{"rendered":"\n<p>A groundbreaking combination therapy has demonstrated significant benefits for patients with KRAS G12C metastatic colorectal cancer that no longer responds to chemotherapy, according to a Phase 3 clinical trial led by researchers at City of Hope. Published in the&nbsp;<a href=\"http:\/\/dx.doi.org\/10.1200\/JCO-24-02026\"><em>Journal of Clinical Oncology<\/em><\/a>, the study reveals that the combination of sotorasib and panitumumab significantly extends progression-free survival, offering new hope for this hard-to-treat patient population.<\/p>\n\n\n\n<p>The trial, named CodeBreaK 300, involved 160 patients with KRAS G12C-mutated colorectal cancer that had progressed despite standard treatments. Participants were divided into three groups: one received a high dose of sotorasib (960 mg) with panitumumab, another received a lower dose (240 mg) with panitumumab, and the third received standard care drugs (trifluridine\/tipiracil or regorafenib).<\/p>\n\n\n\n<p>Results showed that over 30% of patients in the high-dose group achieved a significant reduction in tumor volume, compared to just 1.9% in the standard care group. Additionally, progression-free survival was notably longer in the high-dose group, and early data suggested a 30% improvement in overall survival, though further studies are needed to confirm this finding.<\/p>\n\n\n\n<p>Dr. Marwan Fakih, the study\u2019s senior author, emphasized the potential of this combination as a new standard of care. \u201cThis treatment prolongs disease control and offers a much-needed option for patients who have exhausted other therapies,\u201d he said.<\/p>\n\n\n\n<p>Sotorasib, the first FDA-approved KRAS G12C inhibitor, works by targeting and blocking the mutated KRAS protein, which drives tumor growth. Panitumumab, a monoclonal antibody, inhibits the epidermal growth factor receptor (EGFR), a protein overexpressed in many cancers, including colorectal cancer. Together, these drugs create a synergistic effect, enhancing treatment efficacy.<\/p>\n\n\n\n<p>While the current study focused on later-line therapy, follow-up research is exploring the combination\u2019s potential as a first-line treatment. Common side effects included diarrhea, fatigue, and nausea, but these were manageable.<\/p>\n\n\n\n<p>This innovative therapy represents a significant advancement for patients with KRAS G12C metastatic colorectal cancer, providing a new lifeline where options were previously limited. As further studies unfold, the combination of sotorasib and panitumumab could redefine treatment protocols for this aggressive cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A groundbreaking combination therapy has demonstrated significant benefits for patients with KRAS G12C metastatic colorectal cancer that no longer responds to chemotherapy, according to a Phase 3 clinical trial led by researchers at City of Hope. Published in the&nbsp;Journal of Clinical Oncology, the study reveals that the combination of sotorasib and panitumumab significantly extends progression-free [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1565],"tags":[592,1457,1566],"class_list":["post-4054","post","type-post","status-publish","format-standard","hentry","category-health-medicine","tag-cancer","tag-drug-combination","tag-health-medicine"],"_links":{"self":[{"href":"https:\/\/scientificworld.org\/index.php?rest_route=\/wp\/v2\/posts\/4054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/scientificworld.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/scientificworld.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/scientificworld.org\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/scientificworld.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4054"}],"version-history":[{"count":1,"href":"https:\/\/scientificworld.org\/index.php?rest_route=\/wp\/v2\/posts\/4054\/revisions"}],"predecessor-version":[{"id":4055,"href":"https:\/\/scientificworld.org\/index.php?rest_route=\/wp\/v2\/posts\/4054\/revisions\/4055"}],"wp:attachment":[{"href":"https:\/\/scientificworld.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/scientificworld.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/scientificworld.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}